The Pharmaplan brand transitions to Exyte

Stuttgart, October 8, 2025 – The Pharmaplan brand has now fully transitioned to Exyte, marking an exciting milestone for two established leaders in European biopharma engineering. By bringing together Pharmaplan’s five decades of process engineering and GMP expertise with Exyte’s global EPC capabilities, the company is even better positioned to deliver state-of-the-art facilities for the European life sciences industry.

The transition harmonized procedures across quality, safety, compliance, and operations, enabling a smooth integration into one brand and one organization for Europe. This unified approach strengthens Exyte to better support clients in accelerating the development and production of advanced medicines and therapies.

“The integration of Pharmaplan enhances our ability to deliver with greater speed, precision, and scale,” said Ronan Donohue, President of Exyte’s Global Business Unit Biopharma and Life Sciences. “Together, our teams are shaping the facilities where breakthroughs in medicine will happen.”

Founded more than 50 years ago, Pharmaplan earned a strong reputation in biopharma engineering across Europe. Now, as part of Exyte, its legacy of expertise continues within a global framework. Donohue adds: “With local expertise, global reach, and a shared commitment to excellence, we are moving forward as one team, one name, one global partner.”

“The integration of Pharmaplan enhances our ability to deliver with greater speed, precision, and scale.”

Ronan Donohue, President, Biopharma and Life Sciences